Trulicity (dulaglutide) received its initial U.S. Food and Drug Administration (FDA) approval on November 3, 2014 [1][2]. This approval was for the glycemic control of type 2 diabetes in adults, when used along with diet and exercise [1][3].
What other conditions is Trulicity approved to treat?
Beyond its initial indication, Trulicity has gained FDA approval for additional uses. It is approved for the chronic management of blood glucose in pediatric patients aged 10 years and older with type 2 diabetes mellitus [1][4]. Additionally, Trulicity is indicated to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors [1][5].
When was Trulicity first available in other countries?
Trulicity's availability extends beyond the United States. It received European Medicines Agency (EMA) approval in November 2014 [6]. Other countries also approved Trulicity, with regulatory bodies in Japan and Canada granting approvals in 2015 [7][8].
What is the patent status for Trulicity?
The patent landscape for Trulicity is complex, with numerous patents covering various aspects of the drug, including its composition, methods of use, and manufacturing processes [9]. These patents contribute to the drug's market exclusivity. Information regarding specific patent expiry dates and any challenges can be tracked through resources like DrugPatentWatch.com [9].
How does Trulicity compare to other diabetes medications?
Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist [3]. It belongs to a class of medications that help lower blood sugar levels [3]. Other GLP-1 receptor agonists include semaglutide (Ozempic, Rybelsus, Wegovy), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon) [10]. These medications differ in their dosing frequency, administration methods (injectable or oral), and specific cardiovascular outcome benefits [10]. Trulicity's efficacy and safety profile are evaluated against these and other diabetes treatment classes like metformin, sulfonylureas, and insulin [3][10].
What are the potential side effects of Trulicity?
Common side effects associated with Trulicity include nausea, vomiting, diarrhea, abdominal pain, and decreased appetite [1][3]. More serious potential side effects can include pancreatitis, gallbladder problems, hypoglycemia (low blood sugar) when used with other diabetes medications, kidney problems, and allergic reactions [1][3]. There is also a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies, though it is unknown if Trulicity causes these tumors in humans [1][3].
What is the mechanism of action for Trulicity?
Trulicity works by mimicking the action of the natural incretin hormone GLP-1. It stimulates insulin secretion from the pancreas in a glucose-dependent manner, meaning it releases more insulin when blood sugar levels are high [3]. It also suppresses glucagon secretion, which is a hormone that raises blood sugar [3]. Additionally, Trulicity slows gastric emptying, which contributes to a feeling of fullness and can help reduce food intake [3].
Who manufactures Trulicity?
Trulicity is manufactured by Eli Lilly and Company [2].